Skip to content
10-Q

Quarterly Report

STEMLINE THERAPEUTICS INC

0001104659-18-066974

← back to feed
Filed
Nov 8, 2018 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2018 · Nov 8, 2018 31.8M sh
Short Term Investments Q3 2018 · Sep 30, 2018 $66.86M
Short Term Investments Q3 2018 · Dec 31, 2017 $46.92M
Cash And Equivalents Q3 2018 · Sep 30, 2018 $11.68M
Cash And Equivalents Q3 2018 · Dec 31, 2017 $4.8M
Current Liabilities Q3 2018 · Sep 30, 2018 $17.34M
Current Liabilities Q3 2018 · Dec 31, 2017 $19.84M
Total Liabilities Q3 2018 · Sep 30, 2018 $17.43M
Total Liabilities Q3 2018 · Dec 31, 2017 $19.94M
Current Assets Q3 2018 · Sep 30, 2018 $80.53M
Current Assets Q3 2018 · Dec 31, 2017 $52.19M
Total Assets Q3 2018 · Sep 30, 2018 $80.96M
Total Assets Q3 2018 · Dec 31, 2017 $67.01M
Net Income Q3 2018 · Sep 30, 2018 −$274.1M
Net Income Q3 2018 · Sep 30, 2017 −$16.06M
Net Income Q3 2018 · Sep 30, 2017 −$46.08M
Revenue Q3 2018 · Sep 30, 2018 $500K
Revenue Q3 2018 · Sep 30, 2017 $299.4K
Revenue Q3 2018 · Sep 30, 2017 $898.2K
Operating Cash Flow Q3 2018 · Sep 30, 2017 −$35.89M
Rd Expense Q3 2018 · Sep 30, 2017 $12.42M
Rd Expense Q3 2018 · Sep 30, 2017 $33.52M
Operating Income Q3 2018 · Sep 30, 2017 −$16.27M
Operating Income Q3 2018 · Sep 30, 2017 −$46.62M